

Head Coordinator REIVAC : Dr Odile Launay

CIC founder members :

CIC P-001 Montpellier
Dr. Galtier
 Hôpital Saint Eloi
 80, avenue Augustin Fliche
 34295 Montpellier cedex 05
 Web : <http://cic.chu-montpellier.fr>

CIC P-007 Bichat-Claude Bernard
Dr. Duval
 11^{ème} étage nord
 46, rue Henri Huchard
 75018 Paris

CIC P-501 Clermont-Ferrand
Pr. Dubray
 CHU de Clermont-Ferrand
 B.P 69 - 63000 Clermont-Ferrand
 Web : <http://cic-cpc.chu-clermontferrand.fr>

CIC BT505 de Vaccinologie Cochin-Pasteur
Dr. Launay
 GH Cochin Saint-Vincent de Paul
 Bâtiment Lavoisier
 27, rue du Faubourg Saint-Jacques
 75014 Paris
 Web : <http://www.cicvaccinologie.com>

CIC partners :

CIC P-9301 Lille
Dr. Jozefowicz
 CHRU de Lille
 Hôpital Cardiologique
 Bd du Pr. Leclercq
 59037 Lille
 Web : <http://www.chru.lille.fr/cic.lille>

CIC EC-3 Saint-Etienne
Pr. Lucht
 Hôpital Nord
 47, avenue Albert Raimond
 42270 Saint-Priest-en-Jarez



Institut national de la santé et de la recherche médicale



Coordination team :

- Clinical Study Coordinator
- Clinical Research Engineer
- Quality Engineer
- Clinical Research Assistant
- Clinical Trials Doctor

December 2009

REIVAC Contacts



Tel : +33 (0)1 58 41 29 28 / 39 27
 Fax : +33 (0)1 58 41 29 10

For industrials :
reivac.ind@cch.aphp.fr
For academics :
reivac.ins@cch.aphp.fr

Promote clinical research in vaccinology

Conception Réalisation : **IMMUNO@APHP** (91) - Tél. : 01 69 79 50 70 - 0911/27

Copyright Inserm : Sansonetti Philippe (left picture)
 Copyright Inserm : Thérèse Couderc (right picture)



REIVAC

REIVAC is the French clinical network dedicated to vaccinology. REIVAC was created in 2008 by three “plurithematic” (P) CICs¹ and a biotechnology (BT) CIC. Those CICs have a particular interest in vaccinology and are experienced in academic and industrial researches.

The REIVAC founder members are :

- CIC P-001, Saint-Eloi University Hospital, Montpellier
- CIC P-007, Bichat-Claude Bernard University Hospital, Paris
- CIC P-501, Clermont-Ferrand University Hospital, Clermont-Ferrand
- CIC BT505, Cochin Saint-Vincent de Paul University Hospital, Paris

The new REIVAC partners since 2009

- CIC P-9301, Cardiology University Hospital, Lille
- CIC EC-003, University Hospital, Saint-Etienne

All biomedical researches performed within REIVAC follow the Good Clinical Practices (GCP) and regulations. In effect CICs within REIVAC have agreements from French authorities to carry out clinical researches. REIVAC is a reactive and efficient structure replying to its partners demand, giving short term answers to projects submission.

REIVAC is sponsored by “GIP CeNGEPS”² and Inserm³.

REIVAC mission

Promoting clinical research in Vaccinology :

- To improve the attractiveness of France for the implementation of preventive and therapeutic vaccine trials from pre-clinical to clinical phases (I to III)
- To link up scientists and physicians, as well as industries and academic institutions, in order to develop exploratory research.

REIVAC objectives :

- To improve, harmonise and facilitate the recruitment of volunteers and set up the administrative tasks
- To generate vaccine trials in France and the European Community
- To allow evaluation of innovative concepts resulting from the fundamental research in vaccinology and with design of newly developed vaccines.
- To set up a biobank for the REIVAC members.

Industrial and academic organizations which Trusted REIVAC


Pharmaceutical industries :

Becton Dickinson
GSK
Merck
Sanofi Pasteur
Sanofi Pasteur MSD
Transgène

Academic partners :

Inserm
Institut Pasteur
Paris Descartes University
CEA (Commissariat à l’Energie Atomique)
ANRS (Agence Nationale de Recherche Contre le Sida)

REIVAC Organisation



REIVAC assets

Organisation

- A unique negotiating partner: REIVAC Steering Committee
- A centralized coordination: REIVAC Coordinating team
- Facilitate financial and hospital agreements validation to improve the reactivity with our partners

Scientific skills

- Scientific, clinical and technical expertises in the vaccine field to perform high standard clinical trials in compliance with GCP and the local regulations
- Promotion of new concepts in vaccinology: REIVAC Advisory Committee

Centers of Investigation (CICs)

- Easy recruitment due to :
 - Volunteers electronic database
 - Access to hospitals patients’ active files
- Optimal safety guarantee for patients and volunteers (with adapted procedures for phase I)
- Storage and dispensation facilities for vaccines

1 – CIC Clinical Center of Investigation: public structure dedicated to clinical trials (www.inserm.com)

2 – GIP CeNGEPS: Group of Public Interest from the National Management Trial Centre for Health Products (www.cengeps.com)

3 – Inserm : National Institute of Health and Medical Research (www.inserm.com)